Autor(es):Mostrar menos -

Shi, Xiaoguang ^[1] ; Liu, Rengyun ^[1] ; Basolo, Fulvio ^[2] ; Giannini, Riccardo ^[2] ; Shen, Xiaopei ^[1] ; Teng, Di ^[1] ; Guan, Haixia ^{[3, 4]} ; Shan, Zhongyan ^{[3, 4]} ; Teng, Weiping ^{[3, 4]} ; Musholt, Thomas J. ^[5] ; Al-Kuraya, Khawla ^[6] ; Fugazzola, Laura ^{[7, 8]} ; Colombo, Carla ^{[7, 8]} ; Kebebew, Electron ^[9] ; Jarzab, Barbara ^[10] ; Czarniecka, Agnieszka ^[10] ; Bendlova, Bela ^[11] ; Sykorova, Vlasta ^[11] ; Sobrinho-Simoes, Manuel ^{[12, 13]} ; Soares, Paula ^{[12, 13]} ; Shong, Young Kee ^[14] ; Kim, Tae Yong ^[14] ; Cheng, Sonia ^[15] ; Asa, Sylvia L. ^[15] ; Viola, David ^[16] ; Elisei, Rossella ^[16] ; Yip, Linwah ^[17] ; Mian, Caterina ^[18] ; Vianello, Federica ^[19] ; Wang, Yangang ^[20] ; Zhao, Shihua ^[20] ; Oler, Gisele ^[21] ; Cerutti, Janete M. ^[21] ; Puxeddu, Efisio ^[22] ; Qu, Shen ^[23] ; Wei, Qing ; Xu, Huixiong ^[24] ; O'Neill, Christine J. ^[25] ; Sywak, Mark S. ^[25] ; Clifton-Bligh, Roderick ^[25] ; Lam, Alfred K. ^[26] ; Riesco-Eizaguirre, Garcilaso ^{[27, 28, 29, 30]} ; Santisteban, Pilar ^{[29, 30]} ; Yu, Hongyu ^[31] ; Tallini, Giovanni ^[32] ; Holt, Elizabeth H. ^[33] ; Vasko, Vasily ^[34] ; Xing, Mingzhao ^[1]

Afiliação do(s) autor(es):Mostrar menos -

^[1] Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Lab Cellular & Mol Thyroid Res, Dept Med, Baltimore, MD 21287 - USA

^[2] Dept Surg, Div Pathol, I-56126 Pisa - Italy

^[3] China Med Univ, Hosp 1, Endocrine Inst, Shenyang 110001, Liaoning - Peoples R China

^[4] China Med Univ, Hosp 1, Dept Endocrinol & Metab, Liaoning Prov Key Lab Endocrine Dis, Shenyang 110001, Liaoning - Peoples R China

^[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Endocrine Surg, D-55101 Mainz - Germany

^[6] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, Riyadh 12713 - Saudi Arabia

^[7] IRCCS Ca Granda Policlin, Fdn Inst Ricovero & Cura Carattere Sci, Milan - Italy

^[8] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan - Italy

^[9] NCI, Endocrine Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 - USA

^[10] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, PL-44101 Gliwice - Poland

^[11] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 - Czech Republic

^[12] Univ Porto Ipatimup, Inst Mol Pathol & Immunol, P-4200319 Oporto - Portugal

^[13] Univ Porto, Fac Med, P-4200319 Oporto - Portugal

^[14] Univ Ulsan, Coll Med, Seoul - South Korea

^[15] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4 - Canada

^[16] Univ Pisa, WHO, Endocrine Unit, Dept Clin & Expt Med, Collaborating Ctr Study & Treatment Thyroid Dis &, I-56124 Pisa - Italy

^[17] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 - USA

^[18] Univ Padua, Endocrinol Unit, Dept Med, I-35128 Padua - Italy

^[19] IRCCS, Veneto Inst Oncol, I-35128 Padua - Italy

^[20] Qingdao Univ, Affiliated Hosp, Dept Endocrinol, Qingdao 266003 - Peoples R China

^[21] Univ Fed Sao Paulo, Div Genet, Genet Bases Thyroid Tumor Lab, BR-04039032 Sao Paulo - Brazil

^[22] Univ Perugia, Dept Internal Med, I-06100 Perugia - Italy

^[23] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Endocrinol, Thyroid Inst, Shanghai 200072 - Peoples R China

^[24] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Med Ultrasound, Thyroid Inst, Shanghai 200072 - Peoples R China

^[25] Univ Sydney, Endocrine Surg Unit, Sydney, NSW 2052 - Australia

^[26] Griffith Univ Gold Coast, Canc Mol Pathol Menzies Hlth Inst Queensland, Southport, Qld 4215 - Australia

^[27] Hosp La Paz, Hlth Res Inst, Madrid 28029 - Spain

^[28] Hosp Univ Mostoles, Madrid 28029 - Spain

^[29] CSIC, Spanish Council Res, Biomed Res Inst, Alberto Sols, Madrid 28029 - Spain

^[30] Autonomous Univ Madrid, Madrid 28029 - Spain

^[31] Second Mil Med Univ, Changzheng Hosp, Dept Pathol, Shanghai 200003 - Peoples R China

^[32] Univ Bologna, Osped Bellaria, Anat Pathol Unit, Dept Med, I-40139 Bologna - Italy

^[33] Yale Univ, Sch Med, Dept Internal Med, Endocrine Sect, New Haven, CT 06520 - USA

^[34] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 - USA

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. 101, n. 1, p. 263-273, JAN 2016.
• Citações Web of Science: 74

Resumo

Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval {[}CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC. (AU)

• Processo FAPESP: 12/02902-9 - Investigação do papel dos microRNAs na regulação da expressão do gene C1orf24 em tumores da tiróide humana
• Beneficiário: Janete Maria Cerutti
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/03867-5 - Análise da variação no número de cópias (CNV) de segmentos de DNA em pacientes de uma família com síndrome nem 2ª e mutação p.G533C no gene RET: identificação de regiões associadas à gênese e progressão do carcinoma medular da tiróide
• Beneficiário: Janete Maria Cerutti
• Modalidade de apoio: Auxílio à Pesquisa - Regular